| Nov 22 |
Immunome files to sell 1.80M shares of common stocks by selling shareholders
|
| Nov 15 |
Immunome Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
| Nov 13 |
Immunome, Inc GAAP EPS of -$0.78 misses by $0.21
|
| Nov 13 |
Immunome, Inc. (IMNM) Reports Q3 Loss, Misses Revenue Estimates
|
| Nov 13 |
Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update
|
| Nov 12 |
ImmunityBio (IBRX) Reports Q3 Loss, Tops Revenue Estimates
|
| Nov 5 |
Immunome to Present at Guggenheim’s Inaugural Healthcare Innovation Conference
|
| Oct 29 |
Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021
|
| Oct 18 |
Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium
|
| Oct 8 |
Immunome files to sell 230K shares of common stock for holders
|
